Retatrutide is an investigational triple agonist injection being studied for obesity and type 2 diabetes management. Understanding how to administer retatrutide correctly is essential for anyone participating in a clinical trial involving this medicine. As retatrutide has not yet received marketing authorisation from the MHRA or EMA, it is only available within regulated clinical trials in the UK. This article outlines the subcutaneous injection technique, site selection, dosing schedule, storage requirements, and important safety information — all based on clinical trial protocols and established NHS and Royal College of Nursing guidance for similar injectable medicines.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, but it remains unlicensed in the UK and is only available within regulated clinical trials.

Retatrutide (LY3437943) is an investigational injectable medication under clinical development for the management of obesity and type 2 diabetes mellitus. It belongs to a novel class of agents known as triple agonists, targeting three incretin and metabolic receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist).^[2][9]

By activating GLP-1 receptors, retatrutide is thought to enhance insulin secretion in a glucose-dependent manner, suppress glucagon release, and reduce appetite.^[7][8] GIP receptor activation may further support insulin sensitivity and fat metabolism, whilst glucagon receptor agonism is hypothesised to promote energy expenditure and reduce hepatic fat accumulation.^[4][10] These are largely mechanistic hypotheses or early findings; robust confirmation in humans for retatrutide specifically is still emerging. Phase 2 clinical trials published in the New England Journal of Medicine (2023) reported substantial reductions in body weight and improvements in glycaemic control in participants with obesity and type 2 diabetes, though these findings require confirmation in larger Phase 3 studies.^[1][4]

It is important to note that, as of the time of writing, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), as confirmed by the MHRA medicines database. It is not currently available as a licensed medicine in the UK. Any use outside of approved clinical trials would be outside the scope of standard clinical practice. Patients should always consult their GP or specialist before considering any unlicensed treatment, and should only receive retatrutide within the context of a regulated clinical trial or under appropriate medical supervision.

How to Inject Retatrutide: Step-by-Step Instructions

Retatrutide is administered as a subcutaneous injection using trial-supplied devices; hands must be washed, the site cleaned with an alcohol swab, and the used needle disposed of immediately in an approved sharps container.

Based on the administration protocols used in clinical trials, retatrutide is delivered as a subcutaneous injection — that is, injected into the fatty tissue just beneath the skin. The presentation of the investigational product (pre-filled pen, pre-filled syringe, or vial) may vary between trial sites and phases; always follow the device-specific instructions provided by your clinical trial team, and ensure you have received hands-on training before self-injecting.

The following steps reflect general best practice for subcutaneous self-injection, consistent with Royal College of Nursing (RCN) guidance and NHS patient-facing advice for similar injectable medicines.^[12][13] They are intended as a general reference only and do not replace your trial protocol or investigator's instructions.

Before you begin:

• Wash your hands thoroughly with soap and water for at least 20 seconds.

• Gather all necessary supplies: the trial-supplied device, a new sterile needle (if not pre-attached), alcohol swabs, and an approved sharps disposal container.

• Check the medication: inspect the solution for discolouration, cloudiness, or visible particles. Do not use if the solution appears abnormal.

• Check the expiry date and confirm the correct dose as instructed by your clinical team.

• If the device has been refrigerated, allow it to reach room temperature for the period specified in your trial instructions before injecting, as this may reduce discomfort. Do not assume a standard warm-up time — follow your protocol.

• Some devices require priming before first use; follow the device Instructions for Use provided by the trial team.

1. Administering the injection:
2. Clean the chosen injection site with an alcohol swab and allow it to dry completely.
3. Pinch a fold of skin gently between your thumb and forefinger.
4. Insert the needle at a 45–90 degree angle, depending on the needle length and the thickness of subcutaneous tissue at the site, as advised by your clinical team.
5. Press the plunger or activation button slowly and steadily until the full dose has been delivered.
6. Hold the needle in place for the number of seconds specified in your device instructions before withdrawing, to help ensure the full dose is absorbed.
7. Release the skin fold and apply gentle pressure with a clean swab — do not rub, as this may affect absorption.
8. Dispose of the used needle immediately in your approved sharps container. Never recap needles. Never share pens, needles, or any part of the injection device with another person.

Sharps disposal: Used needles and devices must be disposed of in an approved sharps container. Your clinical trial team, local council, or community pharmacy can advise on collection arrangements in your area.

Always follow the specific instructions provided by your clinical trial team or prescribing clinician, as device design and handling requirements vary between investigational products.

Choosing the Right Injection Site and Technique

The abdomen (at least 5 cm from the navel), outer thigh, and outer upper arm are the recommended subcutaneous injection sites; systematic rotation is essential to prevent lipohypertrophy and ensure consistent absorption.

Selecting an appropriate injection site is important for consistent drug absorption and minimising local skin reactions. For subcutaneous injections such as retatrutide, the sites used in clinical trials — consistent with RCN and NHS guidance for similar agents — include:

• Abdomen: The area at least 5 cm away from the navel is the most commonly used site, offering a relatively large surface area and predictable absorption.

• Thigh: The outer, middle third of the thigh is suitable and easily accessible for self-injection.

• Upper arm: The outer aspect of the upper arm may be used; however, this site generally requires administration by a trained carer or healthcare professional unless the trial protocol and device specifically permit self-use at this location.

Rotation of injection sites is strongly recommended. Injecting repeatedly into the same location can lead to lipohypertrophy — a build-up of fatty tissue beneath the skin — which may impair drug absorption and lead to variable medication delivery. This is well established with insulin and is considered a relevant concern for subcutaneous peptide injections more broadly. A systematic rotation pattern (for example, moving clockwise around the abdomen, or alternating between left and right thigh) helps minimise this risk.

Avoid injecting into areas that are:

• Bruised, tender, or broken

• Affected by skin conditions such as psoriasis or eczema

• Near moles, scars, or areas of lipohypertrophy

Always use a new needle for every injection and do not inject through clothing. If you notice any persistent lumps, hardened areas, or skin changes at injection sites, report these to your clinical trial nurse or GP promptly.

Dosing Schedule and Storage Guidance

Retatrutide is injected once weekly on the same day each week, following a structured dose-escalation schedule defined by the trial protocol; storage conditions are specified by the trial sponsor and must not be assumed from other medicines.

In Phase 2 clinical trials (NEJM, 2023), retatrutide was administered as a once-weekly subcutaneous injection, following a structured dose-escalation schedule. This approach is consistent with other GLP-1-based therapies and is designed to minimise gastrointestinal side effects whilst allowing the body to adjust gradually to the medication. Doses studied in trials ranged from 1 mg up to 12 mg weekly, with escalation occurring over several weeks under medical supervision. Dosing regimens vary between study arms and trial phases; the schedule applicable to you will be defined by your specific trial protocol.

Key points regarding the dosing schedule:

• Consistency: Injections should be administered on the same day each week, at any time of day, with or without food, unless your protocol specifies otherwise.

• Missed dose: If you miss a dose, do not attempt to manage this independently. Contact your clinical trial team for guidance, as missed-dose windows and instructions are defined by the trial protocol and may vary. Do not double-dose to compensate.

• Dose adjustments and treatment interruptions: These should only be made under the guidance of your supervising clinician or trial investigator. Interruptions may require re-titration per protocol.

Storage guidance: Because retatrutide is an investigational product, storage and handling requirements are defined by the trial sponsor, the pharmacy supplying the medication, and the Investigator's Brochure. Do not assume storage conditions based on those of similar licensed medicines. Always follow the instructions on the pharmacy label or those provided by your clinical team. General principles for peptide-based injectables (such as refrigeration and protection from light) may apply, but the specific requirements for your trial supply take precedence.

Store all medicines out of the reach of children at all times. If you are unsure about any aspect of storage or handling, contact your clinical trial team before using the medication.

Common Side Effects and What to Watch For

The most common side effects are gastrointestinal — including nausea, vomiting, and diarrhoea — and are typically mild to moderate; severe abdominal pain, signs of anaphylaxis, or chest pain require immediate emergency attention.

As with other incretin-based therapies, retatrutide is associated with a range of side effects, the majority of which are gastrointestinal in nature and tend to be most pronounced during the dose-escalation phase. Data from Phase 2 trials (NEJM, 2023) indicate that these effects are generally mild to moderate and transient.

Common side effects include:

• Nausea and vomiting

• Diarrhoea or constipation

• Reduced appetite

• Abdominal discomfort or bloating

• Injection site reactions (redness, itching, or mild swelling)

These effects can often be managed by eating smaller, lower-fat meals, avoiding lying down immediately after eating, staying well hydrated, and adhering to the gradual dose-escalation schedule.

Less common but clinically important effects observed in trials include:

• Heart rate increase: Retatrutide, like other GLP-1 receptor agonists, may cause a modest elevation in resting heart rate.^[15] This should be monitored, particularly in individuals with pre-existing cardiovascular conditions.

• Hypoglycaemia: Risk is low when used alone but increases if combined with insulin or sulfonylureas (for example, gliclazide or glibenclamide). If you take either of these medicines, discuss hypoglycaemia management with your clinical team.

• Dehydration and kidney strain: Persistent vomiting or diarrhoea can lead to dehydration and, in some cases, acute kidney injury. Maintain adequate fluid intake and seek medical review if you are unable to keep fluids down.

• Gallbladder-related issues: Rapid weight loss associated with this class of medication may increase the risk of gallstones.

Pregnancy, breastfeeding, and contraception: Retatrutide is an investigational medicine and its safety in pregnancy or breastfeeding has not been established. If you are pregnant, planning a pregnancy, or breastfeeding, inform your clinical trial team immediately. Trial protocols typically require effective contraception during participation; follow the guidance provided by your trial team.

Thyroid considerations: Preclinical studies in rodents — consistent with findings for other GLP-1 receptor agonists as a class — have raised theoretical concerns regarding thyroid C-cell tumours. No causal link has been established in humans for retatrutide or other GLP-1-based medicines. Nonetheless, individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) should discuss this with their clinician before enrolling in any trial involving this class of agent.^[19][20]

When to seek urgent help:

• Call 999 immediately if you experience signs of a severe allergic reaction (anaphylaxis): sudden rash, swelling of the face, lips, tongue or throat, or severe difficulty breathing.

• Call 999 if you experience severe chest pain or collapse.

• Call NHS 111 for urgent advice if your GP or clinical trial team is unavailable and you are concerned about symptoms that are not immediately life-threatening.

• Contact your GP or clinical trial team promptly if you experience: severe or persistent abdominal pain (which could indicate pancreatitis); significant changes in heart rate or palpitations; symptoms of low blood sugar (shakiness, sweating, confusion); or persistent vomiting preventing adequate fluid intake.

Reporting side effects: If you experience a suspected side effect, you or your healthcare professional can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the MHRA Yellow Card app. Reporting helps build the safety evidence base for investigational medicines.

Frequently Asked Questions